Optimizing the Systemic Treatment for Metastatic Castration-Resistant Prostate Cancer in Lower-Middle–Income Countries: A 7-Year Analysis of the Brazilian Public Health System
Authors:
- Fernando Sabino Marques MonteiroFMFernando Sabino Marques Monteiro
- Vinicius Carrera SouzaVSVinicius Carrera Souza
- Karine Martins da TrindadeKTKarine Martins da Trindade
- Adriano Gonçalves e SilvaASAdriano Gonçalves e Silva
- Augusto MotaAMAugusto Mota
- Diogo Assed BastosDBDiogo Assed Bastos
- Douglas Andreas ValverdeDVDouglas Andreas Valverde
- Haonne Soares AbboudHAHaonne Soares Abboud
- Daniel HerchenhornDHDaniel Herchenhorn
- Andrey SoaresASAndrey Soares
Open Access
- 1 March 2026
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500683
Abstract
PURPOSE: Prostate cancer is the most prevalent cancer in men worldwide. As new treatments become available, costs also increase, and patients from lower-middle-income countries do not have access to those treatments due to cost restriction and governmental approval. However, several non–survival-prolonging treatments (nspTx) continue to be offered to patients with metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: We gathered retrospective data from patients with mCRPC treated under the Brazilian Public Health System (BPHS) from 2017 to 2023. Our analysis concentrated on assessing the treatment plans, the median duration of treatment (mDoT), and the costs associated with these plans. The main aim of this study was to clarify the overall expenses, timing, and types of therapies provided to patients with mCRPC. RESULTS: A cohort of 38,851 patients with mCRPC showed a mDoT of 20.5 months and total castration-resistant treatment costs of $333,200,939 US dollars (USD). Among them, 31,430 (81%) received survival-prolonging treatments (spTx), while 7,421 (19%) were given nspTx. The spTx group had a mDoT of 19.8 months, with total spending of $269,892,761 USD and an average cost per patient of $8,587.11 USD. The nspTx group's mDoT was 20.5 months, costing $63,308,180 USD in total and $8,530.95 USD per patient. Exploratory analysis indicated that funds spent on nonsurvival treatments for one patient could cover generic cabazitaxel (20 mg/m 2 once every 21 days, six cycles) for approximately two patients with mCRPC. CONCLUSION: This long-term analysis of the BPHS treatment of mCRPC shows substantial spending on spTx and nspTx. Although most patients received recommended spTx, 19% received nspTx at similar costs. Results indicate the need for reforms to prioritize evidence-based treatments in resource-limited settings.Keywords
This publication has 10 references indexed in Scilit:
- The Lancet Commission on prostate cancer: planning for the surge in casesThe Lancet, 2024
- Prostate cancer temporal and regional trends in BrazilOncology Research, 2024
- COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and OmicronVaccine, 2023
- Health litigation and cancer survival in patients treated in the public health system in a large Brazilian city, 2014–2019BMC Public Health, 2023
- A aprovação da Resolução CNS nº 510/2016 é um avanço para a ciência brasileiraSaúde e Sociedade, 2019
- Brazil's unified health system: the first 30 years and prospects for the futureThe Lancet, 2019
- Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015Journal of Urology, 2018
- Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICAJournal of Clinical Oncology, 2017
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008